Study: When to treat hypertension and intensify treatment

the ONA take:

According to a new study published in the British Medical Journal, researchers at Brigham and Women's Hospital in Boston, Massachusetts, have determined the precise blood pressure level and time points at which intervening with antihypertensives was associated with a decreased risk of death.

Researchers found that that patients with systolic blood pressures between 130 and 150 had no increase in risk, but those with systolic blood pressures above 150 had progressively greater risk of acute cardiovascular event, such as stroke or myocardial infarction, or death.

In addition, they found that delaying intensification of treatment, which was defined as increasing the dosage of antihypertensives or adding new antihypertensives when blood pressure levels increase, by more than 1.4 months was associated with increased risk of cardiovascular event or death.

The team also found that patients who received a blood pressure reassessment more than 2.7 months after treatment intensification had an increased risk of death.

The findings suggest the importance of avoiding treatment delays and follow-up delays for patients with hypertension, particularly those with systolic blood pressure levels greater than 150.

Bevacizumab-induced hypertension is a marker for improved outcomes in recurrent glioblastoma
Precise blood pressure level and time points at which intervening with antihypertensives was associated with a decreased risk of death.
High blood pressure is the most common risk factor for heart disease and death worldwide, and yet the answers to some of the most basic questions about how to manage it - when to introduce new medications, intensify treatment or re-evaluate a patient - remain unclear.
READ FULL ARTICLE From Medical Express
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs